Endometrial cancer stage III

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
2 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 1 substance
PARP inhibitor 1 substance
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Tesaro Inc. Commercial
    DOSTARLIMAB; NIRAPARIB TOSILATE MONOHYDRATE
    2023-506551-23-00 13 countries 2019 n=225
    Ended

Phase II

1 trial
  • Grupo Espanol De Investigacion En Cancer De Ovario Academic
    DOSTARLIMAB
    2024-512021-81-00 1 country 2025 n=25
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Tesaro Inc. Commercial 1 Phase III 0
Grupo Espanol De Investigacion En Cancer De Ovario Academic 1 Phase II 1
New trials by year
2019
1
2025
1
← All indication landscapes